May 19, 2020
Report From Orexo AB's Extraordinary General Meeting, 19 May 2020
May 11, 2020
Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Apr 28, 2020
Orexo Presents the Interim Report for Q1 2020
Apr 16, 2020
James Noble Appointed as Chairman of the Board
Apr 16, 2020
Notice of Extraordinary General Meeting of Orexo
Apr 16, 2020
Report from Orexo's Annual General Meeting, 16 April 2020
Apr 09, 2020
The Board of Directors of Orexo Withdraws Proposal on Incentive Program
Apr 06, 2020
Orexo Ends Share Buy-back Program
Mar 26, 2020
Orexo Publishes the Annual Report for 2019
Mar 25, 2020
Orexo Has Repurchased 14 Percent of Own Corporate Bonds
Mar 17, 2020
Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day
Mar 06, 2020
Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US
Feb 17, 2020
Orexo AB (publ.) has Resolved to Carry out Repurchases of own Shares
Dec 03, 2019
Save the Date: Orexo to Host Capital Markets Day focusing on Digital Health, on March 17, 2020
Dec 02, 2019
Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health
Nov 27, 2019
Orexo Acquires Exclusive US Rights to Commercialize Vorvida®, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy
Nov 08, 2019
Orexo to Present at Jefferies 2019 Healthcare Conference
Oct 24, 2019
Orexo Interim Report Q3 2019
Jul 11, 2019
Orexo Interim Report Q2 2019
Jul 10, 2019
Orexo Signs License and Supply Agreement With Mundipharma for Zubsolv® in Australia and New Zealand